Visen Pharmaceuticals Reports Increased Loss of RMB 118 Million for H1 2025; R&D and Administrative Expenses Rise Significantly
Visen Pharmaceuticals has released its unaudited interim results for the six months ended June 30, 2025. The company reported a significant increase in its cash and cash equivalents, which rose to RMB 805.9 million from RMB 203.6 million as of December 31, 2024. However, Visen Pharmaceuticals experienced a rise in its loss for the period, reporting a loss of RMB 118.0 million compared to a loss of RMB 83.5 million for the same period in 2024. Research and development costs increased to RMB 46.6 million from RMB 38.9 million, and administrative expenses rose to RMB 60.0 million from RMB 43.6 million in the previous year. During this period, the company focused on advancing its drug pipeline and aims to expand its franchise in endocrinology within China, including Hong Kong, Macau, and Taiwan. No significant investments or material acquisitions were made during the reporting period, and the capital structure remained unchanged. The company also did not plan any material investments or capital assets as of the announcement date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on August 27, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.